2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS
申请人:IRONWOOD PHARMACEUTICALS, INC.
公开号:US20150342954A1
公开(公告)日:2015-12-03
Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
2-[1-[(2-FLUOROPHENYL)METHYL]-5-(3-ISOXAZOLYL)-1H-PYRAZOL-3-YL]-PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
申请人:Ironwood Pharmaceuticals, Inc.
公开号:EP3112363A1
公开(公告)日:2017-01-04
2-[1-[(2-Fluorophenyl)methyl]-5-(3-isoxazolyl)-1H-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sGC) stimulators, particularly NO-independent, heme-dependent stimulators, for treating pulmonary hypertension and other diseases.
2-[1-[(2-氟苯基)甲基]-5-(3-异恶唑基)-1H-吡唑-3-基]-嘧啶衍生物及相关化合物,作为可溶性鸟苷酸环化酶(sGC)刺激剂,特别是 NO 依赖性、血红素依赖性刺激剂,用于治疗肺动脉高压和其他疾病。
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
作者:Takashi Nakai、Nicholas R. Perl、Timothy C. Barden、Andrew Carvalho、Angelika Fretzen、Peter Germano、G-Yoon J. Im、Hong Jin、Charles Kim、Thomas W.-H. Lee、Kimberly Long、Joel Moore、Jason M. Rohde、Renee Sarno、Chrissie Segal、Erik O. Solberg、Jenny Tobin、Daniel P. Zimmer、Mark G. Currie
DOI:10.1021/acsmedchemlett.5b00479
日期:2016.5.12
In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of a series of 4-hydroxypyrimidine sGC stimulators starting with an internally discovered lead. Our efforts have led to the discovery of IWP-051, a molecule that achieves good alignment of potency, stability, selectivity, and pharmacodynamic effects while maintaining favorable pharmacokinetic properties with once-daily dosing potential in humans.
2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure